Reproduction note:
Hardcopy version available to institutional subscribers
Origination:
Footnote:
Description:
Naloxone is a life-saving medication which helps reverse the effects of an opioid overdose. Improving naloxone access is a central pillar of the federal response to the worsening opioid crisis in the United States. Existing studies have evaluated the effects of state naloxone access laws, including those that permit naloxone to be dispensed by pharmacies directly to consumers. However, this literature has ignored the role of pharmaceutical innovations like Narcan. Narcan, introduced to the marketplace in February 2016, is a naloxone nasal spray that permits laypersons to successfully administer the drug without training. We first test the hypothesis that naloxone access laws alone increased the distribution of naloxone prior to Narcan, followed by testing the hypothesis that the introduction of Narcan further expanded naloxone's distribution and its life-saving impacts. We analyze cross-state variation in the adoption of naloxone access laws and their timing relative to Narcan's introduction. We find that states with naloxone access laws permitting pharmacists to dispense to consumers experienced substantially greater naloxone dispensing after Narcan's introduction, effects that far outpaced the independent effects of the laws themselves. We also find that while these naloxone access laws did not reduce non-synthetic opioid-related mortality rates on their own, once Narcan was introduced, these mortality rates significantly declined. These findings indicate the important interaction of innovation and policy